WADA Prohibited List is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
On 9 May 2024, control Judge Juan Manuel Fernández López rejected Agüero's appeals against the prosecution's petition to take her to trial, and ordered that she stand trial on five counts of aggravated murder, as well as eight other counts of attempted murder. Along with Agüero, Judge Fernández López also ordered that 10 officials face trial at the same courtroom where Agüero will be tried. The trial against Brenda Agüero and the other ten defendants commenced on 6 January 2025. Agüero denied committing the crimes during her first testimony, saying that there is "no possibility that harming another person crosses my mind; much less a child." On 22 January, the mother of one of the babies who decompensated (a baby girl named Isabella) testified that she saw Agüero injecting her baby while the little girl was in the cradle. The woman said that the baby cried as Agüero injected her shortly before decompensating. On 30 January, medical professionals testified at the trial, saying that the babies did not die from a natural cause, and confirmed that the levels of potassium or insulin in their bodies were injected deliberately. On 4 February, a neonatal doctor testified that during her shift on 6 June 2022, when two healthy babies died without presumptive cause, she saw Brenda Agüero with a baby in her arms, and that Agüero told her that the baby "was not well". The baby later died from a serious case of bradycardia. The doctor also confirmed that the nature of the deaths of these healthy babies raised suspicions from the doctors who attempted to resuscitate them.
The late nineteenth century saw the emergence of New Liberalism within the Liberal Party, which advocated state intervention as a means of guaranteeing freedom and removing obstacles to it such as poverty and unemployment. The policies of the New Liberalism are now known as social liberalism.
==== Adequacy of equipment and regulations ==== The factory was not well equipped to handle the gas created by the sudden addition of water to the MIC tank. The MIC tank alarms had not been working for four years and there was only one manual back-up system, compared to a four-stage system used in the United States. The flare tower and several vent gas scrubbers had been out of service for five months before the disaster. Only one gas scrubber was operating: it could not treat such a large amount of MIC with sodium hydroxide (caustic soda), which would have brought the concentration down to a safe level. The flare tower could only handle a quarter of the gas that leaked in 1984, and moreover it was out of order at the time of the accident. To reduce energy costs, the refrigeration system was idle. The MIC was kept at 20 degrees Celsius, not the 4.5 degrees advised by the manual. Even the steam boiler, intended to clean the pipes, was non-operational for unknown reasons. Slip-blind plates that would have prevented water from pipes being cleaned from leaking into the MIC tanks if the valves had been faulty were not installed and their installation had been omitted from the cleaning checklist. As MIC is water-soluble, deluge guns were in place to contain escaping gases from the stack. The water pressure was too weak for the guns to spray high enough to reach the gas which would have reduced the concentration of escaping gas significantly. In addition to it, carbon steel valves were used at the factory, even though they were known to corrode when exposed to acid.
The Type 1 RNA evolved to be catalytically inactive, but complexing with the Type 5 RNA boosted its polymerization ability and enabled intermolecular interactions with the RNA template substrate obviating the need to tether the template directly to the RNA sequence of the RPR, which was a limitation of earlier studies. Not only did t5(+1) not need tethering to the template, but a primer was not needed either as t5(+1) had the ability to polymerize a template in both 3' → 5' and 5' 3 → 3' directions. A highly evolved RNA polymerase ribozyme was able to function as a reverse transcriptase, that is, it can synthesize a DNA copy using an RNA template. Such an activity is considered to have been crucial for the transition from RNA to DNA genomes during the early history of life on earth. Reverse transcription capability could have arisen as a secondary function of an early RNA-dependent RNA polymerase ribozyme. An RNA sequence that folds into a ribozyme is capable of invading duplexed RNA, rearranging into an open holopolymerase complex, and then searching for a specific RNA promoter sequence, and upon recognition rearrange again into a processive form that polymerizes a complementary strand of the sequence. This ribozyme is capable of extending duplexed RNA by up to 107 nucleotides, and does so without needing to tether the sequence being polymerized. A short 20-nucleotide RNA variant ribozyme was identified that self-reproduces via template directed ligation of two 10 nucleotide oligomers.
Sources: en.wikipedia.org
== Early life == Brian Rafat Awadis was born on November 19, 1996 in San Diego, California, to immigrant Chaldo-Assyrian parents from Tel Keppe, Iraq. His father owns two stores. He graduated from Mira Mesa Senior High School and attended San Diego Miramar College before dropping out during his freshman year to pursue his YouTube career full-time. He can speak the Suret language, although not fluently.
Four years later, in 1934, Minot, Murphy, and Whipple were awarded the Nobel Prize in Physiology or Medicine for their research. In the 1930s, the company also continued its expansion overseas. In 1934, Eli Lilly and Company Limited, the company's first overseas subsidiary, was established in London, and a manufacturing plant was opened in Basingstoke. In 1932, despite the economic challenges of the Great Depression, Lilly's sales rose to $13 million. The same year, Eli Lilly, eldest grandson of Col. Lilly who had joined the company in 1909, was named as the company's president, succeeding his father, who remained as chairman of the board until 1948. In his early years at the company, Eli was especially interested in improving production efficiency and introduced a number of labor-saving devices. He also introduced scientific management principles, implemented cost-savings measures that modernized the company, and expanded the company's research efforts and collaborations with university researchers. Thimerosal, developed by chemist Morris Kharasch at the University of Maryland in the late 1920s, was subsequently marketed by Lilly under the trade name Merthiolate as an antiseptic and preservative. In 1934, the firm opened two new facilities in Indianapolis on the McCarty Street complex: a replica of Lilly's 1876 laboratory and the new Lilly Research Laboratories, "one of the most fully equipped facilities in the world." As part of its research and product development process, Lilly also conducted clinical studies at Indianapolis City Hospital.
=== Phase 1 === AH-001 – topical – alopecia – ubiquitin-protein ligase expression stimulant AMP-303 – intradermal – alopecia – undefined mechanism of action (polysaccharide) CKD-843 – oral, injection – alopecia – undefined mechanism of action CKR-051 – transdermal – alopecia – CXXC5 protein inhibitor, Wnt signalling pathway stimulant DR-01 – parenteral – alopecia areata – antibody-dependent cell cytotoxicity, T lymphocyte stimulant ET-02 (RS-5441) – topical – alopecia, hair disorders – undefined mechanism of action (targets and restores hair follicle stem cells) FOL-100 – topical – alopecia – undefined mechanism of action OLX-72021 – intradermal injection – alopecia – RNA interference QY-201 – oral – alopecia areata – Janus kinase 1 inhibitor, TYK2 kinase inhibitor SCO-240 – oral – alopecia – somatostatin receptor 5 modulator Squaric acid dibutyl ester (SQX-770) – topical – alopecia areata – immunomodulator VDAA – topical – alopecia areata – undefined mechanism of action
Sources: en.wikipedia.org
=== Neuroplasticity === SNRIs do not work immediately; their mood related therapeutic effect builds up over several weeks. Long-term use of SNRIs can change the brain's signaling pathway beyond raising serotonin and norepinephrine. Some studies have shown an increase in BDNF (growth factor) with continued SNRI treatment. BDNF helps the brain adjust and form better connections through synapse strengthening and remodeling. This is also part of the reason why it takes some time for antidepressants to show full benefits. Another aspect of this neuroplastic effect is the adaptation of the pain pathway as well, which may help explain why SNRIs can help with chronic pain.
Because of the practical and, in particular, the financial scale of the program needed, the NCI decided to seek association with a pharmaceutical company, and in August 1989, it published a Cooperative Research and Development Agreement (CRADA) offering its current stock and supply from current bark stocks, and proprietary access to the data so far collected, to a company willing to commit to providing the funds to collect further raw material, isolate taxol, and fund a large proportion of clinical trials. In the words of Goodman and Welsh, authors of a substantial scholarly book on taxol, "The NCI was thinking, not of collaboration, ... but of a hand-over of taxol (and its problems)". Although the offer was widely advertised, only four companies responded to the CRADA, including the American firm Bristol-Myers Squibb (BMS), which was selected as the partner in December 1989. The choice of BMS later became controversial and was the subject of Congressional hearings in 1991 and 1992. While it seems clear the NCI had little choice but to seek a commercial partner, there was also controversy about the terms of the deal, eventually leading to a report by the General Accounting Office in 2003, which concluded the NIH had failed to ensure value for money. In related CRADAs with the USDA and Department of the Interior, Bristol-Myers Squibb was given exclusive first refusal on all Federal supplies of Taxus brevifolia. This exclusive contract lead to some criticism for giving BMS a "cancer monopoly".
=== Floor realizations === After the player has completed all of the Abnormality battles on a floor, they can begin the floor's Realization: a multi-segmented puzzle battle against either Angela or Roland as they suffer from an emotional meltdown, taking after the floor's Abnormalities' appearances and abilities. Completing the Floor realization will grant E.G.O. pages exclusive to that floor. While not mandatory, only through completing all Floor realizations (sans the Kether floor) can the player unlock the game's true ending.
==== School of Community Health and Policy ==== The School of Community Health and Policy offers an American Association of Colleges of Nursing (AACN) accredited program in nursing, degree programs in nutritional sciences and health education, and graduate programs leading to the Master of Public Health, Master of Science, and Doctor of Public Health (DrPH). The university's nursing class of 2018 scored a perfect pass rate, the first perfect score for an entire nursing program class at Morgan, and the only four-year nursing program in Maryland to achieve a 100 percent pass rate that year.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.